HIGHLIGHTS
- who: Antonietta Rosella Farina from the (UNIVERSITY) have published the Article: The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII, in the Journal: (JOURNAL)
- what: The authors propose, therefore, that efforts should be doubled to identify cancers potentially driven by aberrant alternative TrkAIII splicing to extend potential therapeutic options to include small_molecule Trk tyrosine kinase inhibitors, inhibitors of PI3K/Akt/NF-кB signaling, inhibitors of Bcl-2 protein family and/or SOD2 expression, reversal of alternative TrkAIII splicing or novel TRAIL or TRAIL-receptor agonist formulations.
SUMMARY
Important drivers in subpopulations . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.